Innoviva (INVA) Gross Profit (2011 - 2026)
Innoviva's (INVA) quarterly Gross Profit came in at $75.8 million in Q1 2026, up 3.43% YoY from $73.3 million in Q1 2025, and down 67.31% on a QoQ basis from $232.0 million in Q3 2025.
Innoviva (INVA) Gross Profit (2011 - 2026) Analysis & Trends
Innoviva (INVA) has 9 years of Gross Profit data on file, last reported at $75.8 million in Q1 2026.
- Quarterly Gross Profit rose 3.43% year-over-year to $75.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $464.3 million (up 6.37% YoY) and the FY2025 annual result came in at $307.7 million, up 3.87% from the prior year.
- Gross Profit declined to $75.8 million in Q1 2026, from $232.0 million in the prior quarter.
- In the past five years, Gross Profit ranged from a high of $261.9 million in Q3 2022 to a low of -$6.2 million in Q2 2023.
- A 5-year average of $101.0 million and a median of $75.8 million in 2026 frame the typical range for Gross Profit.
- Annual changes were most pronounced in 2023 — Gross Profit slumped 249.76% — and 2024, when it surged 24227.13%.
- Tracing INVA's Gross Profit over 5 years: stood at $261.9 million in 2022, then declined by 14.83% to $223.0 million in 2023, then dropped by 2.22% to $218.1 million in 2024, then rose by 6.38% to $232.0 million in 2025, then sank by 67.31% to $75.8 million in 2026.
- The last three Gross Profit figures came in at $75.8 million (Q1 2026), $232.0 million (Q3 2025), and $83.1 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Innoviva | 1.54 Bn | 968.79 Mn | 90.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 90.62 Mn |
| Jun 30, 2026 | 90.62 Mn |
| Mar 31, 2026 | 75.83 Mn |
| Mar 31, 2026 | 75.83 Mn |
| Sep 30, 2025 | 232.00 Mn |
| Sep 30, 2025 | 232.00 Mn |
| Jun 30, 2025 | 83.15 Mn |
| Jun 30, 2025 | 83.15 Mn |
| Mar 31, 2025 | 73.32 Mn |
| Mar 31, 2025 | 73.32 Mn |
| Sep 30, 2024 | 218.08 Mn |
| Sep 30, 2024 | 218.08 Mn |
| Jun 30, 2024 | 84.99 Mn |
| Jun 30, 2024 | 84.99 Mn |
| Mar 31, 2024 | 60.09 Mn |
| Mar 31, 2024 | 60.09 Mn |
| Sep 30, 2023 | 223.02 Mn |
| Sep 30, 2023 | 223.02 Mn |
| Jun 30, 2023 | -6.15 Mn |
| Jun 30, 2023 | -6.15 Mn |